IBO IMPACT BIOMEDICAL INC.

Impact BioMedical Inc. to Present at The Microcap Conference

Impact BioMedical Inc. to Present at The Microcap Conference

HOUSTON, Jan. 23, 2025 (GLOBE NEWSWIRE) -- Impact BioMedical Inc. (NYSE American: IBO), a pioneering biotechnology company dedicated to discovering, developing, and patenting innovative healthcare solutions, today announced that Frank D. Heuszel, Chief Executive Officer, is pleased to announce his participation in The Microcap Conference 2025, the premier event for growth-focused companies and investors. The conference will take place January 28-30, 2025, at the Borgata Hotel Spa & Casino in Atlantic City, NJ.

Mr. Heuszel will deliver a corporate presentation and engage in one-on-one meetings with investors to discuss the company’s recent developments, growth strategy, and investment opportunities. Details regarding his presentation are below.

Impact BioMedical Inc. Microcap Conference Presentation

Date: Wednesday, January 29, 2025

Time: 10:30 AM ET



About Impact BioMedical, Inc.:

Impact BioMedical Inc. (NYSE American: IBO) discovers, confirms, and patents unique science and technologies which can be developed into new offerings in biopharmaceuticals and consumer healthcare and wellness in collaboration with external partners through research, licensing, co-development, joint ventures, and other relationships.

Investor Relations:



EN
23/01/2025

Underlying

IBOIMPACT BIOMEDICAL INC.

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on IMPACT BIOMEDICAL INC.

 PRESS RELEASE
Free
IBO IMPACT BIOMEDIC...

Impact Biomedical Inc. Announcement Stock Activity/Pricing

Impact Biomedical Inc. Announcement Stock Activity/Pricing HOUSTON, March 21, 2025 (GLOBE NEWSWIRE) -- Impact BioMedical Inc. (NYSE American: IBO), a pioneering biotechnology company dedicated to discovering, developing, and patenting innovative healthcare solutions, today announced that there has been no material development in its business affairs not previously disclosed or, to its knowledge, any other reason to account for the unusual market action regarding its share price. About Impact BioMedical, Inc.: Impact BioMedical Inc. (NYSE American: IBO) discovers, confirms, and patents u...

March 21, 2025 1 EN
 PRESS RELEASE
Free
IBO IMPACT BIOMEDIC...

Impact Biomedical Inc. Announces Acquisition of Celios®, “Protecting P...

Impact Biomedical Inc. Announces Acquisition of Celios®, “Protecting People, Plants, and Animals from the World’s Most Dangerous Pathogens With Clean-Room Air Quality” HOUSTON, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Impact BioMedical Inc. (NYSE American: IBO), a pioneering biotechnology company dedicated to discovering, developing, and patenting innovative healthcare solutions, today announced the acquisition of Celios®, a pioneering air purification technology company, in a strategic, all equity transaction valued at approximately $1.15 million. This acquisition aligns with Impact Biomedical’...

February 26, 2025 1 EN
 PRESS RELEASE
Free
IBO IMPACT BIOMEDIC...

Impact BioMedical Inc. to Present at The Microcap Conference

Impact BioMedical Inc. to Present at The Microcap Conference HOUSTON, Jan. 23, 2025 (GLOBE NEWSWIRE) -- Impact BioMedical Inc. (NYSE American: IBO), a pioneering biotechnology company dedicated to discovering, developing, and patenting innovative healthcare solutions, today announced that Frank D. Heuszel, Chief Executive Officer, is pleased to announce his participation in The Microcap Conference 2025, the premier event for growth-focused companies and investors. The conference will take place January 28-30, 2025, at the Borgata Hotel Spa & Casino in Atlantic City, NJ. Mr. Heuszel will ...

January 23, 2025 1 EN
 PRESS RELEASE
Free
IBO IMPACT BIOMEDIC...

Impact BioMedical Inc. Issues Shareholder Letter Highlighting Recent A...

Impact BioMedical Inc. Issues Shareholder Letter Highlighting Recent Achievements and Strategic Vision HOUSTON, Nov. 19, 2024 (GLOBE NEWSWIRE) -- Impact BioMedical Inc. (NYSE American: IBO), a pioneering biotechnology company dedicated to discovering, developing, and patenting innovative healthcare solutions, today announced that Frank D. Heuszel, Chairman and Chief Executive Officer of Impact BioMedical Inc., issued the following letter to Impact BioMedical shareholders regarding recent achievements, executional efficiencies and the positive outlook for the Company’s future. Dear Impact...

November 19, 2024 1 EN
 PRESS RELEASE
Free
IBO IMPACT BIOMEDIC...

Impact BioMedical Inc. Announces Issuance of Canadian Patent for Lineb...

Impact BioMedical Inc. Announces Issuance of Canadian Patent for Linebacker™ Technology Targeting Inflammatory Disease HOUSTON, Oct. 15, 2024 (GLOBE NEWSWIRE) -- Impact BioMedical Inc. (NYSE: IBO), is thrilled to announce a significant milestone in its innovative Linebacker™ technology platform. The Canadian Intellectual Property Office has issued Canadian Patent #3,024,728 entitled “Electrophilically Enhanced Phenolic Compounds for Treating Inflammatory Related Diseases and Disorders". This patent includes claims to novel enhanced phenolic compounds and pharmaceutical compositions as wel...

October 15, 2024 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch